A New Approach To Produce [18F]MC225 Via One-Step Synthesis, A PET Radiotracer For Measuring P-gp Function.

Lara Garcia Varela  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen  
https://orcid.org/0000-0001-9803-4708

Khaled Attia  
Symeres, Kadijk 3,9747 AT Groningen

John Carlo Sembrano  
Symeres, Kadijk 3, 9747 AT Groningen

Olivier Jacquet  
Symeres, Kadijk 3, 9747 AT Groningen

Inês farinha antunes  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen

Chantal Kwizera  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen

Ton J. Visser  
Symeres, Kadijk 3, 9747, AT Groningen

Rudi A.J.O. Dierckx  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen

Philip H. Elsinga  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen

Gert Luurtsema  
University Medical Centre Groningen: Universitair Medisch Centrum Groningen

---

Research article

**Keywords:** P-glycoprotein (P-gp), Parkinson's Disease, radiosynthesis, mesylate precursor

**DOI:** https://doi.org/10.21203/rs.3.rs-377973/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: \(^{[18}\text{F}]\text{MC225}\) is a radiotracer for imaging P-glycoprotein (P-gp) function at the blood-brain barrier. The P-gp function can be altered due to different factors, for instance, decreased P-gp function has been described in patients with Alzheimer’s or Parkinson’s Disease. The current applied radiosynthesis of \(^{[18}\text{F}]\text{MC225}\) involves 2 steps, including the distillation of \(^{[18}\text{F}]\text{fluoroethylbromide}\) intermediate. To develop a more robust synthetic procedure, it is of interest to produce the radiotracer via 1-step synthesis. The present study describes a new synthetic approach to produce \(^{[18}\text{F}]\text{MC225}\) via direct \(^{18}\text{F}\)-fluorination. Moreover, we also provide the appropriate conditions for the automation of the synthesis. A mesylate precursor was developed via a multi-step synthetic route and used for the radiolabeling. The nucleophilic substitution of the mesylate group by \(^{[18}\text{F}]\text{Fluoride}\) was automated in two different synthesis modules: IBA Synthera and Eckert and Ziegler (E&Z).

Results: The mesylate precursor was synthesized in 7 steps starting with 5-hydroxy-1-tetralone (commercially available) in practical yields. The stability of the precursor was improved via mesylate salt formation method. The radiolabeling was done by adding the mesylate precursor dissolved in DMF to the dried \(^{[18}\text{F}]\text{KF/Kryptofix}_{222}\) complex and heating at 140°C for 30 min. Quality control by UPLC confirmed the production of \(^{[18}\text{F}]\text{MC225}\) with a molar activity (A\(_m\)) higher than 20000 GBq/mmol. The synthesis time in Synthera was 106 min and the product was obtained with a radiochemical purity higher than 95% and RCY of 6.5%, while the production in E&Z lasted 120 min and the product had a lower radiochemical purity (91%) and RCY (3.8%).

Conclusions: \(^{[18}\text{F}]\text{MC225}\) was successfully produced via a 1-step reaction. The procedure is suitable for automation using commercially available synthesis modules. The automation of the radiosynthesis in the Synthera module allows the production of the \(^{[18}\text{F}]\text{MC225}\) by a reliable and simple method.

Background

\(^{[18}\text{F}]\text{MC225}\) is a radiotracer for imaging P-glycoprotein (P-gp) function at the blood-brain barrier (BBB) \(^{1,2}\). P-gp is an efflux transporter located in the luminal side of the cerebral endothelial cells which constitute the main component of the BBB \(^{3,4}\). P-gp belongs to the ATP-Binding Cassette transporter family, their function is ATP-dependent and apart from the BBB, these transporters are also located in several tissues involved in absorption and excretion functions such as the intestine, testes, placenta, kidneys, and liver \(^{5}\). In the BBB, the main function of P-gp is to transport a wide variety of substances out of the brain to the blood. Therefore, this transporter contributes to limit the permeability of the BBB and protects the Central Nervous System (CNS) from neurotoxic compounds \(^{5}\).

However, the P-gp function can be altered due to different factors. Many unrelated xenobiotic compounds can increase the P-gp expression and function which leads to reduced concentration of drugs in the desired target causing decreases in drug efficacy \(^{6-10}\). Moreover, dysfunctions in P-gp function have been
observed in various disease conditions. For instance, patients with intractable epilepsy, have shown increased P-gp expression and function in isolated brain capillaries. Also, a decreased P-gp function has been reported in Alzheimer's and Parkinson's disease. Therefore, the assessment of P-gp function using Positron Emission Tomography (PET) imaging can help to improve the diagnosis of certain CNS diseases where the P-gp function is altered. In addition, this technique can also evaluate treatments that affect P-gp function.

\[^{18}\text{F}\]MC225 has been developed as a weak substrate of the P-gp transporter. Thus, this radiotracer showed a higher brain uptake at baseline conditions, which allows us to measure both increased and decreased P-gp function at the BBB in rats. Previous evaluation of the radiotracer in vivo has shown good pharmacokinetic properties, an adequate signal-to-noise ratio, high sensitivity toward the target, and low levels of radio-metabolites inside the brain. All these characteristics make \[^{18}\text{F}\]MC225 a suitable radiotracer and worthwhile to perform clinical studies to evaluate the P-gp function in the human brain.

For the validation of \[^{18}\text{F}\]MC225 for clinical use, the production must be compliant with Good Manufacturing Practice (GMP). The currently used GMP-synthesis of \[^{18}\text{F}\]MC225 (Figure 1) implies two synthesis steps, including a distillation step of the \[^{18}\text{F}\]fluoroethylbromide intermediate. Unfortunately, this relatively time-consuming and complex procedure results in low radiochemical yields. Thus, it may be convenient to simplify the radiotracer synthesis via 1-step procedure to make the reaction simpler, and thus more robust.

Therefore, this study aims to produce \[^{18}\text{F}\]MC225 via a 1-step reaction using a new MC225 precursor compound which allows the production of the radiotracer by direct \(^{18}\text{F}\)-fluorination. Moreover, the study discusses the most appropriate conditions for the automation of the synthesis.

**Methods**

**Synthesis of phenol precursor (Figure 2)**

5-[3-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydro-naphthalen-1-ol, called the phenol precursor was synthesized as previously described but with some modifications on the synthesis route (Figure 2). 5-Hydroxy-1-tetralone is commercially available (Combi Blocks) and was protected with a benzyl group as follow: 5-Hydroxy tetralone (1, 5.0 g, 30.9 mmol, 1.0 eq.) and potassium carbonate (8.5 g, 61.7 mmol, 2.0 eq.) dissolved in ACN were stirred for 15 minutes at room temperature under \(\text{N}_2\)-atmosphere. Benzyl bromide (4.04 mL, 33.9 mmol, 1.1 eq.) was added and the resulting beige suspension was stirred overnight at room temperature under \(\text{N}_2\)-atmosphere. The reaction mixture was concentrated in vacuum and the crude material was partitioned between water (50 mL) and DCM (50 mL). The layers were separated, and the organic layer was successively washed with water (50 mL), a saturated aqueous solution of NaHCO\(_3\) (50 mL), and brine (50 mL). The organic layer was collected, dried
with anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuum to give a beige oil which slowly solidified on standing. The solids were triturated with heptane (30 mL) to give 5-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one (2) as a crystalline white solid (6.5 g, 83% of yield). $^1$H-NMR (300 MHz, CDCl$_3$) $\delta$ 7.68 (dd, $J = 7.9, 1.1$ Hz, 1H), 7.54 – 7.18 (m, 7H), 7.08 (dd, $J = 8.1, 1.2$ Hz, 1H), 5.11 (s, 2H), 2.98 (t, $J = 6.2$ Hz, 2H), 2.64 (dd, $J = 7.5, 5.7$ Hz, 2H), 2.27 – 1.97 (m, 2H).

For the next step, the benzylated product (compound 2) was reacted with freshly prepared Grignard reagent. Magnesium turnings (0.96 g, 39.7 mmol, 2.0 eq.), anhydrous THF (30 mL), and iodine (1 grain, catalytic) were combined in a flame-dried three-necked flask under N$_2$-atmosphere. Cyclopropyl bromide (2.4 mL, 39.7 mmol, 2.0 eq.) was added portion-wise (total addition time = 15 minutes). After the complete addition of the bromide, the mixture was slowly heated to 55°C. The color of the mixture turned from brown to colorless accompanied by slight effervescence. The resulting mixture was stirred at 55°C for 2h at room temperature under N$_2$-atmosphere. At this point, the color of the reaction turned yellowish and the magnesium turnings were completely consumed. The Grignard reagent (CypPrMgBr) was cooled to 0°C by using an ice bath and compound 2 (5.0 g, 19.8 mmol, 1.0 eq.) dissolved in anhydrous THF (30 mL) was added. The resulting mixture was stirred at reflux overnight under N$_2$-atmosphere. The mixture was then quenched with a saturated solution of NH$_4$Cl (100 mL). Diethyl ether (100 mL) was added, and the mixture was stirred for 15 minutes at room temperature. The layers were separated, and the aqueous layer was extracted with diethyl ether (1× 25 mL). The organic layers were combined, washed with brine (50 mL), collected, dried with anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuum to give a yellow oil (6.4 g). The crude was used as such in the next step without purification.

After the Grignard reaction, the cyclopropyl ring was opened by using hydrochloric acid in acetic acid. Thus, the crude material was dissolved in glacial acetic acid (100 mL) and a 20% aqueous solution of HCl (100 mL) was added. The resulting solution was stirred for 2h at room temperature. The acidic mixture was then concentrated in vacuum and the crude was dissolved in DCM (100 mL). The solution was washed with a saturated solution of NaHCO$_3$ (3× 100 mL), water (100 mL), and brine (25 mL). The organic layer was collected, dried with anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuum to give 8-(benzyloxy)-4-(3-chloropropyl)-1,2-dihydronaphthalene and (E)-5-(benzyloxy)-1-(3-chloropropylidene)-1,2,3,4-tetrahydronaphthalene (3) as a brown oil (5.4 g, 87% of yield). No purification was performed regarding the presence of isomers and thus, the isolated material was used as such in the next step.

The crude mixture containing compound 3 (5.4 g, 19.8 mmol, 1.0 eq.) was dissolved in DMF (100 mL). Anhydrous Na$_2$CO$_3$ (6.3 g, 59.4 mmol, 3.0 eq.) was added along with commercially available (Combi Blocks) 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (5.75 g, 29.7 mmol, 1.5 eq.). The mixture was stirred overnight at 100°C under N$_2$-atmosphere. The mixture was allowed to cool down to room temperature. The mixture was partitioned between ethyl acetate (250 mL) and water (250 mL). The organic layer was collected, washed with water (3× 100 mL), collected, dried with anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuum to give (Z)-2-(3-(5-(benzyloxy)-3,4-dihydronaphthalen-1-yl)propyl)-6,7-dimethoxy-
1,2,3,4-tetrahydroisoquinoline and (E)-2-(3-(5-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-ylidene)propyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline mixture (4) compounds as a brown oil (8.2 g, quantitative). No purification was performed due to the presence of isomers and thus, the isolated material was used as such in the next step.

Subsequently, a hydrogenation step was carried out to reduce double bonds of both isomers and to cleave the benzyl protecting group in one step. Therefore, the isomeric mixture 4 (8.2 g, 17.5 mmol, 1.0 eq.) was dissolved in a mixture of absolute ethanol (100 mL) and DMF (100 mL). This mixture was stirred under N₂-atmosphere for 15 minutes. To this mixture was added, palladium on carbon (Pd/C) (10wt% loading, 1.86 g, 1.75 mmol, 0.1 eq.). The resulting mixture was stirred for 48h at room temperature under H₂-atmosphere (atmospheric pressure) to remove the benzyl group. The mixture was filtered over a thin path of Celite and the filtrate was concentrated in vacuum, dissolved in EtOAc (100 mL), washed with water (4× 100 mL), and brine (100 mL). The organic layer was collected, dried with anhydrous Na₂SO₄, filtered, and concentrated in vacuum to give the crude containing the phenol. The crude was purified via silica column chromatography (DCM: MeOH, 95:5). The fractions that contain the pure compound were concentrated in vacuum to afford 5-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydronaphthalen-1-ol (5) compound as an off-white foam (1.82 g, 25% yield calculated from benzylated intermediate (2)). ¹H NMR (300 MHz, CDCl₃) δ 6.98 (t, J = 7.8 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), 6.62 – 6.49 (m, 3H), 3.84 (d, J = 1.6 Hz, 6H), 3.57 (s, 2H), 2.88 – 2.45 (m, 9H), 1.92 – 1.57 (m, 8H).

Compound 5 (50.0 mg, 1 eq, 131 µmol) was dissolved in DMF (3 mL) and sodium hydride (15.7 mg, 5 eq, 655 µmol) was added to the dissolved compound. The resulting mixture was stirred for 20 min until no further gas evolution was observed. 1-Bromo-2-fluoroethane (33.3 mg, 20 µL, 2 eq, 262 µmol) was added drop-wise to the reaction mixture. The reaction was monitored by LC-MS. After 20 min of stirring at room temperature, the reaction was complete. The reaction mixture was quenched by addition to a mixture of water/ethylacetate (50 mL/50 mL). The organic layer was separated and the aqueous layer extracted with ethyl acetate (2x100 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude material was purified by automated column chromatography yielding non labelled MC225 (35.0 mg, 62.5 %). ¹H NMR (299 MHz, CDCl₃) δ 7.08 (t, J = 7.9 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 6.59 (s, 1H), 6.52 (s, 1H), 4.90 – 4.77 (m, 1H), 4.75 – 4.57 (m, 1H), 4.24 (dd, J = 5.0, 3.4 Hz, 1H), 4.20 – 4.10 (m, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.56 (s, 3H), 2.93 – 2.76 (m, 3H), 2.76 – 2.63 (m, 3H), 2.58 – 2.46 (m, 2H), 1.98 – 1.52 (m, 9H).

Synthesis mesylate precursor (Figure 3).

5-(3-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydronaphthalen-1-ol (5) (150.0 mg, 1 eq, 393.2 µmol) (phenol precursor or 5) was dissolved in DMF (12 mL) and sodium hydride (47.18 mg, 5 eq, 1.97 mmol) was added to the dissolved compound. The resulting mixture was stirred for 2 hours until no gas evolution appeared anymore. ((2-Bromoethoxy)methyl)benzene (169 mg, 0.124 mL, 1.99 eq, 784 µmol) was added drop-wise to the reaction, and the progress of the reaction was monitored
by LC-MS. After 20 min of stirring the reaction was completed according to LC-MS. The reaction mixture was quenched by adding to a mixture of water/ethyl acetate (50 mL/50 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (2x100 mL). The combined organic layers were dried over anhydrous Na$_2$SO$_4$ and evaporated under reduced pressure. The compound was analyzed by HPLC-MS. The crude material was purified by automated column chromatography (Biotage Purification System, Uppsala, Sweden) with a gradient of 0% to 50% ethyl acetate in heptane yielding 2-(3-(5-(2-(benzyloxy)ethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (6) (165 mg, 84.4%). $^1$H NMR (300 MHz, CDCl$_3$) δ 7.43 – 7.28 (m, 5H), 7.07 (t, $J = 7.9$ Hz, 1H), 6.81 (d, $J = 7.7$ Hz, 1H), 6.67 – 6.61 (m, 1H), 6.59 (s, 1H), 6.52 (s, 1H), 4.65 (s, 2H), 4.14 (dd, $J = 5.8, 4.1$ Hz, 2H), 3.90 – 3.78 (m, 8H), 3.55 (s, 2H), 2.91 – 2.76 (m, 3H), 2.76 – 2.62 (m, 4H), 2.58 – 2.44 (m, 2H), 1.91 – 1.60 (m, 8H).

A solution of 6 (150.00 mg, 1 eq., 290.87 µmol) in methanol (12 mL) and acetic acid (0.5 mL) was stirred under N$_2$ for 20 min. Pd/C (20.00 mg, 0.5 Eq, 29.09 µmol) was added to the solution and the reaction was stirred overnight at 5 bar H$_2$ pressure. After 3 days of stirring full conversion was observed. The mixture was filtered through a pad of Celite and the organic solvents were removed by rotary evaporation. The residue was dissolved in ethyl acetate and washed with a potassium bicarbonate solution. The organic layer was dried over anhydrous Na$_2$SO$_4$, filtered, and evaporated under reduced pressure yielding 2-((5-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)ethan-1-ol (7) (100.20 mg, 81%). $^1$H NMR (299 MHz, cdcl$_3$) δ 7.08 (t, $J = 7.9$ Hz, 1H), 6.84 (d, $J = 7.8$ Hz, 1H), 6.65 (d, $J = 8.0$ Hz, 1H), 6.59 (s, 1H), 6.52 (s, 1H), 4.07 (dd, $J = 5.2, 3.7$ Hz, 2H), 3.97 (dd, $J = 5.2, 3.6$ Hz, 2H), 3.84 (d, $J = 2.1$ Hz, 6H), 3.56 (s, 2H), 2.89 – 2.76 (m, 3H), 2.76 – 2.65 (m, 3H), 2.57 – 2.46 (m, 2H), 1.93 – 1.51 (m, 9H).

Compound 7 (105.00 mg, 1 eq., 246.73 µmol) was used without further purification and was dissolved in 1,4-dioxane (8 mL) and methanesulfonic anhydride (45.13 mg, 1.05 eq., 259.06 µmol) was added to the mixture. The resulting mixture was heated to reflux during one week until the reaction was complete. The reaction mixture was evaporated under reduced pressure, and 6,7-dimethoxy-2-(3-(5-((methylsulfonyl)oxy)ethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)-1,2,3,4-tetrahydroisoquinolin-2-ium methanesulfonate (8) MC225 precursor was isolated as its mesylate salt. At this stage, we could not isolate intermediate 8 in pure form (93 mg, 75 % pure,) and decided to use it as such for the radiolabeling.

$^{[18]}$Fluoride production

$^{[18]}$F Fluoride was produced using a cyclotron (IBA Cyclone, Louvain-la-Neuve, Belgium) by the nuclear reaction $^{18}$O(p,n)$^{18}$F.

Automated synthesis (Figure 4)

The synthesis was automated using two different modules the IBA Synthera module (Figure 5) and the Modular Lab PharmTracer from Eckert & Ziegler (Figure 6). Aqueous $^{[18]}$F fluoride was trapped on Sep-Pak
Light Accell Plus QMA anion exchange cartridge (Waters, Milford, USA) previously conditioned with 5 ml of Na\(_2\)CO\(_3\) 1.4%, washed with 10 ml of H\(_2\)O for injection, and then dried with a nitrogen stream.

\[^{18}\text{F}]\text{Fluoride was eluted using a solution of 1.3±0.12 mg K}_2\text{CO}_3\) and 7.1±0.26 mg Kryptofix 222 in 1 ml of ACN/H\(_2\)O (8:2). Azeotropic drying of the \[^{18}\text{F}]\text{KF/Kryptofix}_{222}\) complex was performed at 110°C under an argon flow and adding 1 ml of ACN. After the evaporation of the solvent, the procedure was repeated twice using 0.5 ml of ACN.

Immediately after the azeotropic drying, 1 mg of mesylate precursor dissolved in 1 ml DMF (or 0.5 ml in the case of E&Z) was added to the reactor vial containing the dried \[^{18}\text{F}]\text{KF/kryptofix}_{222}\) complex. The reaction was heated at 140°C for 30 min and after cooling down the solution 1 ml of H\(_2\)O was added (1.3 ml in case of E&Z). The crude reaction was injected onto the semi-preparative HPLC and the product was collected after 12 min.

Purification of the crude reaction was done in a semi-preparative HPLC system using a Symmetryshield RP8 5µm 7.8 x 300 mm column. 0.1 M NaOAc/ACN (5.5/4.5) (v/v) (pH = 4.7) were used as eluent at a flow of 3 ml/min. The UV signal was measured at a wavelength of 215 nm.

Formulation of the product

Formulation of the product was done as previously described \(^1\). Briefly, the desired product eluted at 12 min from the Prep-HPLC was collected in an 80 ml sterile H\(_2\)O bottle. The mixture was mixed with helium and the mixture was passed through an Oasis HLB 1 cm\(^3\) (30 mg) extraction cartridge where the product was trapped. The cartridge was washed twice with 8 ml sterile H\(_2\)O and the product was eluted with 1 ml of ethanol. Next, 4 ml of 0.9% NaCl\(_2\) was passed through the cartridge to formulate the final product. The solution was filtered through a Millipore Millex LG Filter (0.2 µm) before collection in a sterile vial.

Quality control methods

Quality control was executed with a Waters Acquity H-class UPLC system (Milford, CT, USA) as previously described \(^2\). The system used a Berthold FlowXStar LB 513 as a radioactivity detector (Bad Wildbad, Germany) and a Waters Acquity UPLC BEH Shield RP18 1.7µm (3.0mmx50mm) column. The product eluted after 3.5 minutes using ACN / 10Mm NH\(_4\)CO\(_3\) (pH=9.5) (50/50) at a flow rate of 0.8 ml/min. The UV detection was set to 215 nm. The reference compound (non-labelled MC225) was used to prepare a calibration curve to know the amount of non-labelled compound and thus the molar activity (A\(_m\)) of the final product at the end of the radiosynthesis.

Results And Discussion
This study aimed to develop a new synthesis method to produce the PET radiotracer $[^{18}\text{F}]$MC225 via a 1-step synthesis. To this purpose, a mesylate precursor has been developed to facilitate direct $^{18}\text{F}$-fluorination yielding $[^{18}\text{F}]$MC225.

This mesylate precursor (8) was synthesized from the phenol precursor (5) which was previously used in the 2-step synthesis of $[^{18}\text{F}]$MC225. Phenol precursor (5) was produced via an alternative synthesis which uses a benzyl-protected tetralone (2). The benzyl protecting group was chosen to reduce both the double bonds of both isomers (4) and to cleave the benzyl protecting group in one step. Palladium on carbon (Pd/C) was used as a catalyst and the hydrogenation was performed at atmospheric pressure. Full reduction of the double bonds was observed after stirring the mixture for 2 h at room temperature. The reaction was run for 48h to remove the benzyl group. Moreover, the benzylated species were more stable than the unprotected phenol. At the end of the synthesis, the phenol precursor (5) was isolated and purified via column chromatography and obtained in a 25% yield (calculated from intermediate 2, Figure 2).

The development of the mesylate precursor (8) was challenging. Firstly, the deprotection of the benzyl group of compound 6 was facing difficulties. Compound 6 seems to be unstable on silica thus reaction needs to achieve quantitative conversion to continue with the next step without further purification. The reaction was slow and different batches of Pd/C and Pd/C hydroxide were added to speed up the reaction and to obtain a maximum conversion. The reaction took more than one week to reach full conversion. Moreover, the reaction mixture needed to be slightly acidic to be able to reach completion, thus acetic acid was added. In the following step, compound 7 was used without further purification, and therefore, it was dissolved in dioxane and reacted with methanesulfonic anhydride at reflux. However, the mesylate precursor was not stable. Especially basic workup of the reaction mixture resulted in the elimination of the mesylate. Several strategies were explored to stabilize compound 8. Eventually, it was observed that the mesylate salt formed during reaction with methanesulfonic anhydride was reasonably stable and helped to stabilize the precursor for a longer time. However, the final mesylate precursor showed several impurities (purity 75%). Therefore, several attempts were made to improve purity e.g., via RP-automated column chromatography, prep HPLC and precipitation. All these attempts were unsuccessful leading to the deterioration of the product on the column or the isolation of impure product in very low yield after precipitation. Thus, the crude reaction mixture was evaporated and used as such for the labeling experiments.

The radiolabeling was performed by adding the mesylate precursor to the dried $[^{18}\text{F}]-\text{KF/krytofix}_{222}$ complex and heating at 140 °C for 30 minutes. After the radiochemistry reaction, the crude mixture was purified using semi-preparative HPLC (as described in the methods) (Figure 7).

The automated synthesis was performed using two modules: IBA Synthera Synthesis Module and the Modular Lab PharmTracer (Eckert & Ziegler). The best results were obtained with IBA Synthera module. The final product produced by both modules was analyzed by UPLC. Table 1 shows the results of both synthesis modules. The total synthesis time was 20 min shorter in the Synthera module than with E&Z
module, mainly because of the faster drying process of the $^{18}$F-KF/Kryptofix$_{222}$ complex. The radiochemical purity of $[^{18}\text{F}]\text{MC225}$ and the radiochemical yield (RCY) corrected for decay was higher in the IBA module. However, a high $A_m$ of the final product was obtained with both modules. Regarding the preparation for the synthesis, the set-up of the synthesis was easier and quicker in the IBA Synthera than in the E&Z module. Although the Modular Lab PharmTracer from E&Z allows the configuration of multi-step and complicated synthesis by the combination of various disposable components, the amount of tubing and valves make the preparation more laborious. In the case of Synthera, the cartridge provides the connections and only the reagents must be placed in the right position during the preparation, thus the time spent in the preparation is shorter. For this reason, Synthera may be a preferable module to perform this synthesis.

Table 1: Characteristics of the 1-step synthesis performed in Eckert & Ziegler and IBA Synthera. Values reported in mean ±SD

| Procedure          | Total Reaction time (min) | Drying time (min) | RCY (%) | % Area$[^{18}\text{F}]\text{MC225}$ (UPLC) | Molar Activity ($A_m$) (GBq/ mmol) |
|--------------------|---------------------------|-------------------|---------|-----------------------------------------|-----------------------------------|
| Eckert & Ziegler   | 120.44 ± 26.33            | 20.33 ± 5.89      | 3.76 ± 2| 91.70 ± 3.8                             | > 20000                           |
| IBA Synthera       | 106.09 ± 13.06            | 10.44 ± 0.73      | 6.53 ± 3| 97.14 ± 1.12                            | > 20000                           |

The final product collected from the semi-preparative HPLC was injected onto the UPLC system to perform quality control. Figure 8 shows an example of UPLC chromatography that shows the desired product appearing at 3.5 min after the injection.

**Conclusion**

Overall, the production of $[^{18}\text{F}]\text{MC225}$ by the 1-step synthesis using the mesylate precursor and the IBA Synthera module seems to be the most successful automated method. The highest radiochemical yield and the adequate purity and $A_m$ of the final product will enable the use of this procedure for GMP productions.

This study provides an alternative method for the production of $[^{18}\text{F}]\text{MC225}$ using a 1-step approach. However, to obtain a GMP compliant synthesis a suitable purification of the mesylate precursor is still warranted. Nevertheless, an automated synthesis using the mesylate precursor and the IBA Synthera module produced $[^{18}\text{F}]\text{MC225}$ in a reliable and simple manner. Quality control performed with UPLC...
ensures an adequate purity and $A_m$ of the final product. Moreover, the 1-step synthesis may be a more attractive method for the translation of the synthesis to other PET centers.

**Abbreviations**

Acetonitrile: ACN

Ammonium chloride: NH$_4$Cl

Blood-brain barrier: BBB

Central Nervous System: CNS

Cyclopropyl magnesium bromide: CypPrMgBr

Dichloromethane: DCM

Dimethylformamide: DMF

Ethyl acetate: EtOAc

Good Manufacturing Practice: GMP

High-performance liquid chromatography-mass spectroscopy: HPLC-MS

Hour: h

Hydrochloric acid: HCl

Hydrogen atmosphere: H$_2$-atmosphere

Liquid chromatography-mass spectroscopy: LC-MS

Methanol: MeOH

Micrometer: µm

Milligram: mg

Milliliter: ml

Minute: min

Molar activity: $A_m$

Nanometer: nm
Nitrogen atmosphere: N\textsubscript{2}-atmosphere

Palladium on carbon: Pd/C

P-glycoprotein: P-gp

Positron Emission Tomography: PET

Potassium carbonate: K\textsubscript{2}CO\textsubscript{3}

Proton nuclear magnetic resonance: H-NMR

Radiochemical yield: RCY

Reverse Phase automated column chromatography: RP-automated column chromatography

Sodium acetate: NaOAc

Sodium bicarbonate: NaHCO\textsubscript{3}

Sodium carbonate: Na\textsubscript{2}CO\textsubscript{3}

Sodium chloride: NaCl

Sodium sulfate: Na\textsubscript{2}SO\textsubscript{4}

Tetrahydrofuran: THF

Thin Layer Chromatography: TLC

Ultra-performance liquid chromatography: UPLC

Ultraviolet: UV

Water: H\textsubscript{2}O

**Declarations**

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Availability of data and material**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

**Authors' contributions**

LGV performed the automated radiosynthesis, analyzed the data, and wrote the manuscript. KA performed the synthesis of the phenol and mesylate precursor, contributed to the automation of the radiosynthesis, the interpretation of the data, and the preparation of the manuscript. JCS and OJ helped in the synthesis of the phenol and mesylate precursor and commented on the final manuscript, IFA commented on the final manuscript, CK helped in the automation of the radiosynthesis and the UPLC analysis, TJV supervised the phenol and mesylate precursor synthesis, helped in the interpretation of the data and commented on the final manuscript, RAJOD commented on the final manuscript and PHE and GL supervised and designed the study, contributed to the interpretation of the data and in the preparation of the manuscript.

**Acknowledgments**

The authors would like to thank Rolf Zijlma and Bram Maas for the UPLC analysis and the technical support.

**References**

1. Savolainen H, Cantore M, Colabufo NA, Elsinga PH, Windhorst AD, Luurtsema G. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier. Mol Pharm. 2015;12:2265–75.

2. Savolainen H, Windhorst AD, Elsinga PH, Cantore M, Colabufo NA, Willemsen AT, et al. Evaluation of [18 F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood–brain barrier in rats: Kinetics, metabolism, and selectivity. J Cereb Blood Flow Metab. 2017;37:1286–98.

3. Appelboom G, Detappe A, LoPresti M, Kunjachan S, Mitrasinovic S, Goldman S, et al. Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery. Neuro Oncol. 2016;18:1601–9.

4. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37:13–25.

5. Mahringer A, Fricker G. ABC transporters at the blood–brain barrier. Expert Opin Drug Metab Toxicol. 2016;12:499–508.
6. Wen J, Shen Y, Zhang M, Wang C, Xiang Y, Cai H, et al. Dexamethasone changes the pharmacokinetics of amitriptyline and reduces its accumulation in rat brain: The roles of P-gp and cyp3a2. *J Pharmacol Sci* 2019;: 0–7.

7. Durk MR, Fan J, Sun H, Yang Y, Pang H, Pang KS, et al. Vitamin D Receptor Activation Induces P-Glycoprotein and Increases Brain Efflux of Quinidine: An Intracerebral Microdialysis Study in Conscious Rats. Pharm Res. 2015;32:1128–40.

8. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, et al. St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model - Role of P-glycoprotein. Brain Pathol. 2014;24:18–24.

9. Perloff MD, Von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica. 2004;34:133–50.

10. Bjorn Bauer, Anika MS, Hartz G, Fricker. and DSM. Pregnane X Receptor Up-Regulation of P-Glycoprotein Expression and Transport Function at the Blood-Brain Barrier. Mol Pharmacol. 2004;66:413–29.

11. Feldmann M, Koepp M. P-glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [11 C]-verapamil. Epilepsia. 2012;53:60–3.

12. Hartz AMS, Pekcec A, Soldner ELB, Zhong Y, Schlichtiger J, Bauer B. P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy. Mol Pharm. 2017;14:999–1011.

13. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76:22–76.

14. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, et al. Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications. Clin Pharmacol Ther. 2009;86:368–77.

15. García-Varela L, Arif WM, Vállez García D, Kakiuchi T, Ohba H, Harada N, et al. Pharmacokinetic Modeling of [18 F]MC225 for Quantification of the P-Glycoprotein Function at the Blood–Brain Barrier in Non-Human Primates with PET. *Mol Pharm* 2020;: acs.molpharmaceut.0c00514.

16. van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Berardi F, de Jong JR, et al. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. *J Med Chem*. 2009;52:4524–32.

**Figures**
Figure 1

the 2-step synthesis of [18F]MC225.

Figure 2

Alternative route for synthesizing the phenol precursor.
Figure 3

Synthesis of the MC225 mesylate precursor as its mesylate salt.

Figure 4

One-step radiosynthesis of [18F]MC225 using the MC225 mesylate precursor.
**Figure 5**

Scheme IBA Synthera module for the 1-step synthesis of [18F]MC225.

**Figure 6**

Scheme of Eckert & Ziegler module for the synthesis of [18F]MC225 using a 1-step procedure.
Figure 7

(A) Crude reaction (30 min at 140°C), the product appeared after 10-11 minutes injection and (B) retention of reference compound MC225 (10-11 min)
Figure 8

Final product injected into the UPLC system. [18F]MC225 elutes at 3.5 min.